Curis Lifescien. Stock Price Today (NSE: CURIS)
Fundamental Score
Curis Lifescien. Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Curis Lifescien. share price today is ₹127.00, up +0.00% on NSE/BSE as of 1 December 2025. Curis Lifescien. (CURIS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹102.67 (Cr). The 52-week high for CURIS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 16.80x, CURIS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 55.32% and a debt-to-equity ratio of 0.96.
Curis Lifescien. Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Curis Lifescien. Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Curis Lifesciences Share Price: A Financial Stability Analysis
The pharmaceutical industry, often described as recession-resistant due to the constant demand for healthcare, nonetheless faces its own set of challenges, including stringent regulatory hurdles and intense competition. This analysis focuses on the financial stability of Curis Lifesciences, specifically examining the factors influencing the Curis Lifescien. share price. A key metric in this evaluation is the company's Return on Capital Employed (ROCE) and its valuation relative to its peers.
Currently, Curis Lifesciences is trading at a price of ₹127.0, with a Price-to-Earnings (PE) ratio of 16.8. This PE ratio suggests how much investors are willing to pay for each rupee of earnings. A higher PE can indicate optimism about future growth, but it can also represent an overvaluation. The ROCE of 34.24% is a noteworthy indicator of profitability. ROCE demonstrates how effectively Curis Lifesciences is generating profits from its capital employed. This high ROCE significantly strengthens the company's economic moat, providing it with a competitive edge over companies struggling to achieve similar levels of capital efficiency, although sustaining this ROCE will require careful capital allocation and strategic investments.
When comparing Curis Lifesciences to its sector peers, such as
Mankind Pharma Ltd, differences in management quality become apparent, though this observation is based purely on publicly available information. While Mankind Pharma Ltd may be perceived to have stronger brand recognition, Curis Lifesciences' impressive ROCE suggests they are effectively utilizing their resources. Companies like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd also operate in similar therapeutic areas but may have distinct financial profiles in terms of debt levels and revenue diversification. A deeper dive into these factors is warranted for a holistic assessment.It is important to note that this analysis is part of a comprehensive, 80-parameter fundamental audit verified by Sweta Mishra. The conclusions are based on publicly available data and observed trends, providing an unbiased perspective on the financial health of Curis Lifesciences. Factors beyond quantitative data like industry trends, regulatory changes and unforeseen Black Swan events may impact the Curis Lifesciences Share Price.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Curis Lifescien. Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CURIS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Return on Equity (55.32%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (34.24%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 16.80 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Interest Coverage (8.45x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.03%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Curis Lifescien. Financial Statements
Comprehensive financial data for Curis Lifescien. including income statement, balance sheet and cash flow
About CURIS (Curis Lifescien.)
Curis Lifescien. (CURIS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current ...market capitalisation of ₹102.67 (Cr). Curis Lifescien. has delivered a Return on Equity (ROE) of 55.32% and a ROCE of 34.24%. The debt-to-equity ratio stands at 0.96, reflecting the company's capital structure. Investors tracking CURIS share price can monitor key metrics including P/E ratio, promoter holding of 68.03%, and quarterly earnings growth.
Company Details
CURIS Share Price: Frequently Asked Questions
What is the current share price of Curis Lifescien. (CURIS)?
As of 01 Dec 2025, 04:21 pm IST, Curis Lifescien. share price is ₹127.00. The CURIS stock has a market capitalisation of ₹102.67 (Cr) on NSE/BSE.
Is CURIS share price Overvalued or Undervalued?
CURIS share price is currently trading at a P/E ratio of 16.80x, compared to the industry average of 31.77x. Based on this relative valuation, the Curis Lifescien. stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of CURIS share price?
The 52-week high of CURIS share price is ₹N/A and the 52-week low is ₹N/A. These values are updated daily from NSE/BSE price data.
What factors affect the Curis Lifescien. share price?
Key factors influencing CURIS share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Curis Lifescien. a good stock for long-term investment?
Curis Lifescien. shows a 5-year Profit Growth of N/A% and an ROE of 55.32%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.96 before investing in CURIS shares.
How does Curis Lifescien. compare with its industry peers?
Curis Lifescien. competes with major peers in the Pharmaceuticals. Investors should compare CURIS share price P/E of 16.80x and ROE of 55.32% against the industry averages to determine competitive standing.
What is the P/E ratio of CURIS and what does it mean?
CURIS share price has a P/E ratio of 16.80x compared to the industry average of 31.77x. Investors pay ₹17 for every ₹1 of annual earnings.
How is CURIS performing according to Bull Run's analysis?
CURIS has a Bull Run fundamental score of 7.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CURIS belong to?
CURIS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Curis Lifescien. share price.
What is Return on Equity (ROE) and why is it important for CURIS?
CURIS has an ROE of 55.32%, which indicates excellent management efficiency. ROE measures how efficiently Curis Lifescien. generates profits from shareholders capital.
How is CURIS debt-to-equity ratio and what does it indicate?
CURIS has a debt-to-equity ratio of 0.96, which indicates moderate leverage that should be monitored.
What is CURIS dividend yield and is it a good dividend stock?
CURIS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Curis Lifescien. shares.
How has CURIS share price grown over the past 5 years?
CURIS has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in CURIS and why does it matter?
Promoters hold 68.03% of CURIS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Curis Lifescien..
What is CURIS market capitalisation category?
CURIS has a market capitalisation of ₹103 crores, placing it in the Small-cap category.
How volatile is CURIS stock?
CURIS has a beta of N/A. A beta > 1 suggests the Curis Lifescien. stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CURIS operating profit margin trend?
CURIS has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is CURIS quarterly performance?
Recent quarterly performance shows Curis Lifescien. YoY Sales Growth of N/A% and YoY Profit Growth of N/A%.
What is the institutional holding pattern in CURIS?
CURIS has FII holding of 2.93% and DII holding of 10.86%. Significant institutional holding often suggests professional confidence in the Curis Lifescien. stock.